In children with new-onset T1D, the administration of autologous CD4+CD25highCD127− has been demonstrated to be safe and well-tolerated, while in some T1D patients’ insulin requirement significantly decreased after receiving Treg therapy suggesting reduced disease severity [91,96]. Here, CD4 is linked to type 1 diabetes mellitus.